Zenas BioPharma (ZBIO) CEO-linked entities purchase 60,000 shares in open market

Zenas BioPharma (ZBIO) reported Q2 results with a doubled net loss but FDA acceptance of its BLA for obexelimab in IgG4-related disease, with a target action date of May 27, 2027. The company also announced pipeline updates, including ongoing trials and international partnerships.

Zenas BioPharma, Inc. (ZBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Obexelimab BLA submission for the treatment of IgG4-RD accepted by FDA; PDUFA target action date of May 27, 2027 - - New study data confirm bioequivalence of obexelimab sing

Zenas BioPharma (NASDAQ:ZBIO) reported positive Phase 3 INDIGO trial results for obexelimab in IgG4-related disease on June 2. The study met primary and key secondary endpoints, including a 56% reduction in flare risk vs placebo and lower glucocorticoid use. The company submitted a Biologics License Application to the FDA in May.

Zenas BioPharma (Nasdaq: ZBIO) said it submitted a Biologics License Application to the U.S. FDA for obexelimab in IgG4-related disease, based on Phase 3 INDIGO results. The trial met the primary endpoint with a 56% reduction in flare risk vs placebo (HR 0.44, p=0.0005) and met four key secondary endpoints, with generally good tolerability.

AB InBev's Stella Artois replaces Heineken as the official beer sponsor of the UEFA Champions League, paying around 200 million euros annually, higher than Heineken's 120 million euros. The deal aligns with AB InBev's strategy to link brands with global events, according to CEO Michel Doukeris.

UBS initiated coverage of CoreWeave with a buy rating and $120 price target, citing strong AI compute demand and revenue growth. Shares have fallen 18% over three months due to debt concerns, but UBS believes risks are peaking. Analysts are mostly bullish, with 28 of 41 recommending buy or strong buy.